Sana Biotechnology Inc.’s recently made public that its Director Yang Patrick Y acquired Company’s shares for reported $0.2 million on Mar 21. In the deal valued at $7.30 per share,28,000 shares were bought. As a result of this transaction, Yang Patrick Y now holds 174,250 shares worth roughly $ 1.0 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, MacDonald James J. sold 333 shares, generating $2,091 in total proceeds. Upon selling the shares at $6.28, the EVP & General Counsel now owns 429,417 shares.
Before that, AGARWAL SUNIL sold 1,627 shares. Sana Biotechnology Inc. shares valued at $42,302 were divested by the EVP, Head of Development & CMO at a price of $26.00 per share. As a result of the transaction, AGARWAL SUNIL now holds 1,550,000 shares, worth roughly $8.9 million.
In the meantime, Morgan Stanley initiated its Sana Biotechnology Inc. [SANA] rating to an Overweight in a research note published on Tuesday, March 01, 2021; the price target was $40. PT values the company’s stock at a premium of 85.65 to its Tuesday closing price. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in early March with a ‘”a Neutral”‘ rating. Goldman began covering SANA with a “Neutral” recommendation on March 01, 2021. BofA Securities started covering the stock on March 01, 2021. It rated SANA as “a Buy”.
Price Performance Review of SANA
On Tuesday, Sana Biotechnology Inc. [NASDAQ:SANA] saw its stock jump 11.46% to $5.74. On the same session, the stock had its day’s lowest price of $5.20, but rose to a high of $5.97. Over the last five days, the stock has gained 37.98%. Sana Biotechnology Inc. shares have fallen nearly -62.92% since the year began. Nevertheless, the stocks have fallen -72.03% over the past one year. While a 52-week high of $26.60 was reached on 01/03/22, a 52-week low of $3.92 was recorded on 06/14/22. SMA at 50 days reached $6.12, while 200 days put it at $12.68. A total of 1.74 million shares were traded, compared to the trading of 1.26 million shares in the previous session.
Levels Of Support And Resistance For SANA Stock
The 24-hour chart illustrates a support level at 5.30, which if violated will result in even more drops to 4.87. On the upside, there is a resistance level at 6.07. A further resistance level may holdings at 6.41. The Relative Strength Index (RSI) on the 14-day chart is 56.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 11.25%. Stochastics %K at 72.23% indicates the stock is a holding.
Sana Biotechnology Inc. [SANA] – Who Are The Largest Shareholders?
In filings from Baillie Gifford & Co., it is revealed that the company now owns 11,085,861 shares, or roughly 5.85% of the outstanding SANA shares. In other words, the investor’s shares have fallen by -176,169 from its previous 13-F filing of 11262030.0. Additionally, Canada Pension Plan Investment Bo decreased 0.00% of its stake after which the total value it holdings stand at $52,197,750, while The Vanguard Group, Inc. reduced -0.34% of its stake to hold $38.4 million in the firm. Over the last quarter, SSgA Funds Management, Inc. purchased 3,614,591 shares of Sana Biotechnology Inc., while BlackRock Fund Advisors bought 179,445 shares. At present, The Public Sector Pension Investm is holding 4,131,249 shares valued at $21.19 million. Crestline Management LP owned 3,210,937 shares of the company at the time of its most recent 13F filing, worth $16.47 million.
According to FactSet, Sana Biotechnology Inc.’s share price will average $12.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 152.43 percent from its previous closing price of $5.15. Analysts expect Sana Biotechnology Inc. stock to reach the higher price of $15.00, while the lowest price estimate is $7.00. However, 4 analysts have rated SANA stock as an Overweight in their predictions for 2022.